Abstract
In addition to its enormous impacts on an individuals quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the obesity-associated morbidities, such as hypertension, glucose intolerance, dyslipidemia, and fatty liver diseases. However, the modification of lifestyle in a case of established clinical obesity is very difficult to achieve. Recent breakthroughs in relation to the molecular mechanism regulating body weight and energy metabolism give us hopes for the development of anti-obesity drugs. Even with the high social demand for an effective treatment for obesity and extensive researches, both in academia and the pharmaceutical industry, only two weight-loss drugs, sibutramine and orlistat, have been approved by the FDA for long-term treatment. In addition, the current bottleneck in drug discovery shows that a more detailed understanding of the pathogenesis of obesity is an essential element for the development of efficacious treatment. In this review article, we focus on the structural origin of chemical entities for anti-obesity treatment along with the rationale for drug discovery, rather than categorizing the clinical efficacy or pharmacological target of obesity. For the clarification of the structural origin, we formed a collection with 4 major groups, including natural products, natural product mimetics, synthetic small molecules, and peptides/hormones. This analysis might provide strategic plans for medicinal chemists, biologists, and physicians to begin an optimistic era with a new class of pharmaceutical adjuncts for obesity therapy.
Keywords: Obesity, satiety, energy expenditure, structural origins, anti-obesity drugs
Current Topics in Medicinal Chemistry
Title: Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities
Volume: 9 Issue: 6
Author(s): Sangmi Oh, Koon Soon Kim, Young Sun Chung, Minho Shong and Seung Bum Park
Affiliation:
Keywords: Obesity, satiety, energy expenditure, structural origins, anti-obesity drugs
Abstract: In addition to its enormous impacts on an individuals quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the obesity-associated morbidities, such as hypertension, glucose intolerance, dyslipidemia, and fatty liver diseases. However, the modification of lifestyle in a case of established clinical obesity is very difficult to achieve. Recent breakthroughs in relation to the molecular mechanism regulating body weight and energy metabolism give us hopes for the development of anti-obesity drugs. Even with the high social demand for an effective treatment for obesity and extensive researches, both in academia and the pharmaceutical industry, only two weight-loss drugs, sibutramine and orlistat, have been approved by the FDA for long-term treatment. In addition, the current bottleneck in drug discovery shows that a more detailed understanding of the pathogenesis of obesity is an essential element for the development of efficacious treatment. In this review article, we focus on the structural origin of chemical entities for anti-obesity treatment along with the rationale for drug discovery, rather than categorizing the clinical efficacy or pharmacological target of obesity. For the clarification of the structural origin, we formed a collection with 4 major groups, including natural products, natural product mimetics, synthetic small molecules, and peptides/hormones. This analysis might provide strategic plans for medicinal chemists, biologists, and physicians to begin an optimistic era with a new class of pharmaceutical adjuncts for obesity therapy.
Export Options
About this article
Cite this article as:
Oh Sangmi, Kim Soon Koon, Chung Sun Young, Shong Minho and Park Bum Seung, Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities, Current Topics in Medicinal Chemistry 2009; 9 (6) . https://dx.doi.org/10.2174/156802609788897862
DOI https://dx.doi.org/10.2174/156802609788897862 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Computational Approaches on Angiotensin Receptors and Their Ligands: Recent Developments and Results
Current Medicinal Chemistry Individual Triptan Selection in Migraine Attack Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Hypothyroidism and Atherosclerosis-Possible Implication of the Renin-Angiotensin System
Current Hypertension Reviews Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry Role of Chymase in Preeclampsia
Current Vascular Pharmacology Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Human Use of Leucoselect® Phytosome® with Special Reference to Inflammatory- Allergic Pathologies in Frail Elderly Patients
Current Pharmaceutical Design Obstructive Sleep Apnea as an Independent Stroke Risk Factor: Possible Mechanisms
Current Molecular Medicine Hypertension, Nitric Oxide, Oxidants, and Dietary Plant Polyphenols
Current Pharmaceutical Biotechnology A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews Differential Impacts of Antihypertensive Drugs on Central Blood Pressure and Their Clinical Significance
Current Hypertension Reviews Renin-Angiotensin System in Diabetes
Protein & Peptide Letters Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology
Current Drug Metabolism Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study
Vascular Disease Prevention (Discontinued) An Overview of the Actions of Capsaicin and Its Receptor, TRPV1, and Their Relations to Small Primary Sensory Neurons
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: The Last Five Years of the Randomized Studies
Current Diabetes Reviews Heart Rate as a Therapeutic Target in Angina Pectoris
Current Pharmaceutical Design Hormonal Effects on Drug Metabolism Through the CYP System: Perspectives on Their Potential Significance in the Era of Pharmacogenomics
Current Drug Targets - Immune, Endocrine & Metabolic Disorders